Adverse events are anticipated during a clinical development program. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We describe here the process undertaken by Pfizer to investigate a safety signal for pancreatic cancer with tofacitinib. Potential cases of pancreatic cancer across indications from Pfizer's clinical trials and safety databases were identified and underwent in-depth case review and external expert consultation. The magnitude of the signal was quantified. The feasibility of formal signal evaluation via a hypothesis-testing study was explored. As of July 2016, 14 cases of potential pancreatic cancer were identified: eight cases in clinical development trials (psoriasis n = 6; RA n = 1; psoriatic arthritis n = 1), four cases in a postmarketing study in RA patients in Japan, and two spontaneous reports. Incidence rates (95% confidence intervals) per 100 patient-years ranged from 0 (0, 0.02) to 0.14 in RA, 0.05 (0.01, 0.15) to 0.07 (0.02, 0.16) in psoriasis, and 0.25 (0.01, 1.37) in psoriatic arthritis. The majority of patients had established risk factors for pancreatic cancer. The pharmaceutical industry's rapid and transparent response to safety signals is essential for ensuring patient safety and enabling physicians and patients to adequately assess a drug's risk:benefit. Safety signals emerging through pharmacovigilance may be true or false indicators of a causative association with drug exposure. In this example, it was determined that tofacitinib exposure was unlikely to be related to induction and promotion of pancreatic cancer; however, a relationship with pancreatic cancer promotion could not be excluded. Abbreviations: ASRs, age standardized incidence rates; EPAR, European Public Assessment Report; IRR, incidence rate ratio; KPNC, Kaiser Permanente Northern California; PDAC, pancreatic ductal adenocarcinoma; SBA, Summary Basis of Approval; SEER, Surveillance, Epidemiology, and End Results database; SIRs, standardized incidence rates; THIN, The Health Improvement Network UK database.
researchers, and is particularly difficult with infrequent adverse events.
Upon identifying a safety signal, the signal must be further refined to ascertain whether an association between the event and the drug exists. Specifically, cases must be reviewed for biologic plausibility and potential confounding factors, and the signal must be quantified and contextualized. Finally, causality between product exposure and safety outcomes may be assessed via formal epidemiological hypothesis-testing studies (signal evaluation). 2 Careful and comprehensive signal refinement and evaluation efforts are of paramount importance, and have substantial implications for patient welfare. Here, we describe a case study concerning the drug tofacitinib to illustrate the complexities and challenges of refining and evaluating a signal for an infrequent adverse event.
| Tofacitinib: background to the case study
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). A 5 mg twice daily (BID) dose of tofacitinib was first approved for the treatment of RA in the US in November 2012 and is now available in more than 80 countries for the treatment of moderate to severe RA. An 11 mg once daily extended-release formulation of tofacitinib had first approval in the US in 2016 and now is approved in additional countries at a global level. 3 Tofacitinib 5 and 10 mg BID doses are currently in clinical development for other immune-mediated inflammatory conditions such as psoriatic arthritis and ulcerative colitis. Tofacitinib has also been evaluated for psoriasis, Crohn's disease, ankylosing spondylitis, and as an antirejection agent in renal allograft transplant. The total tofacitinib clinical development program is extensive, having included more than 13 000 patients and provided more than 29 000 patient-years (PYs) of exposure (up to November 2015; cut-off date used for the original signal evaluation). 4 In addition, postmarketing experience accrued in patients with RA amounted to more than 45 000 PYs of exposure to tofacitinib (to April 2016; cut-off date used for the original signal evaluation). 4 Postmarketing surveillance studies are ongoing in the US and other countries where tofacitinib is approved for the treatment of
RA, including a US Consortium of Rheumatology Researchers of
North America (CORRONA) registry postapproval safety study (NCT01402661), a postmarketing safety study of tofacitinib vs tumor necrosis factor (TNF) inhibitors in subjects with RA (A3921133; NCT02092467), and a Japanese postmarketing all-case surveillance study (A3921194; NCT01932372).
Patients with chronic autoimmune and inflammatory diseases are at increased risk of developing certain types of malignancies, 5 and immunomodulatory therapies for these conditions have also been associated with a further increased risk. 6 Tofacitinib has a novel mechanism of action and, therefore, safety events of special interest that might relate to its effects on the immune system (eg, malignancies and serious infections) have been closely monitored throughout its clinical development. and Helicobacter pylori infection. 10, 11 In this case study, we describe the process undertaken by Pfizer to investigate (ie, identify, refine and evaluate) a signal for pancreatic cancer with tofacitinib therapy, as well as the conclusions and actions from the investigation. By describing this investigation, it is hoped that healthcare professionals can acquire further insight into this aspect of the drug development process and to the importance of timely, complete reports of adverse events.
| MATERIALS AND METHODS

| Signal identification
The signal for pancreatic cancer with tofacitinib was initially identi- 
| Signal contextualization
Having characterized the case series, their occurrence was quantified and considered in the context of the overall exposed population and other populations, ie, contextualized. Five experts in epidemiology/ pharmacoepidemiology reviewed high-level details of the cases, the estimated incidence rates (IRs)/standardized incidence rates (SIRs), and the epidemiology analysis plan for investigation of the signal. Helicobacter pylori infection, obesity, etc., due to the inability to measure these factors either in the study and/or reference populations.
Definitions of pancreatic cancer differed across comparator data sources. Pancreatic cancers in the SEER and Japanese registries and the KPNC comparison cohort were defined as any invasive or in situ pathology type within specific sites of the pancreas (ICD-10 code C25); KPNC cases were adjudicated. Within THIN, the definition included only invasive neoplasms within similar sites, as well as ectopic pancreatic tissue; these cases were not adjudicated.
SIRs were not calculated for the tofacitinib RA program as there were no cases in the Phase 1, 2, or 3 studies, or long-term extension studies, and the remaining cases occurred in an ongoing trial, a Japanese postmarketing study, and from spontaneous reports where overall demographic data were not available.
| Signal evaluation
Pfizer commissioned a feasibility assessment for the evaluation of the signal in the postmarketing clinical practice setting.
3 | RESULTS
| Signal identification
The initial signal identification is described in the methods section. RA n = 1; psoriatic arthritis n = 1), four cases in a postmarketing study in RA patients in Japan, and two spontaneous reports ( Thus, induction was deemed implausible for all cases.
The panel then considered the cases with respect to promoting tumor progression. Any potential effect on tumor promotion was thought to be very unlikely for the four cases with clinical presentation beginning <6 months after the start of tofacitinib treatment.
Such cases were removed from the sensitivity analyses for the contextualization of events in the psoriasis program as described below.
Although thought by the experts to be unlikely, a role in promotion could not be excluded in the remaining four cases (three of which occurred in the psoriasis program) in which tofacitinib-exposure time until clinical presentation ranged from 339 to 946 days.
| Contextualization of the signal
Patient exposure by indication and the IRs of pancreatic cancer per 100 PYs are shown in Table 2 . For comparison, there were no pancreatic cancer cases among malignancies reported in EPARs/SBAs for apremilast 15, 16 and secukinumab, 17, 18 and one case of pancreatic cancer was reported in the etanercept EPAR. 19 However, patient follow-up was considerably shorter in those clinical development programs than in the tofacitinib program. In the tofacitinib program, 68% of participants were followed up for >1 year, compared with 35% to 48% with etanercept, secukinumab, and apremilast; furthermore, 45% of tofacitinib patients were followed up for >2 years, compared with 13% and 3% for adalimumab and apremilast, Case excluded from PDAC classification by expert panel review due to absence of abnormalities on CT scan of pancreas; note that the patient had been exposed to adalimumab in the index study and was exposed to tofacitinib for 84 days prior to diagnosis. Pfizer, data on file). Among RA populations, rates ranged from 0.01 to 0.04 per 100 PYs across US (Pfizer, data on file) and EU 22 disease registries, respectively.
Standardized incidence ratios and IRRs were produced for the PDAC cases within the psoriasis program using THIN and KPNC (all psoriasis and moderate to severe psoriasis) comparison cohorts as reference populations using a December 2015 data cut, as shown in Table 3 . These analyses adjust for time-varying age, gender, diabetes, and smoking status. The SIRs based on an earlier data cut (described in Table 2 ), and which adjusted for more limited covariates and also used Japan and US SEER general population reference populations (not shown), were consistent with results of the updated analyses. Age-and gender-adjusted SIRs based on the 5 cases of pancreatic cancer, regardless of plausibility, reported in the psoriasis program were five to~ninefold higher than expected.
A sensitivity analysis was conducted censoring the exposure within the first 6 months of tofacitinib (including 2 possible pancreatic cancer cases, as their relationship to tofacitinib was considered by independent experts to be implausible). Age-and gender-adjusted SIRs Excluding the first 6 months, based on expert input that cases occurring within 6 or 12 months of exposure should be excluded from IR estimates; the sponsor took a conservative approach and selected 6 months. The patient was exposed to adalimumab in the index study and was exposed to tofacitinib for 84 days prior to diagnosis.
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| Interpretation of results
The overall conclusion of the independent medical oncologists' and epidemiologists' review of the data was that, despite the elevated SIR within the psoriasis development program, they considered it unlikely that tofacitinib had a role in the etiology of pancreatic cancer based on the evidence associating both pancreatic cancer with immunosuppression and small molecule drugs as promoters of tumor growth/progression, and also the known latency of PDAC in relation to tofacitinib-exposure times. Given the above, the majority of experts deemed the signal most likely due to chance or selection bias.
| Signal evaluation
Given that tofacitinib is currently approved for RA, and the majority of its use is in the US, the study population required to evaluate the signal in the postmarketing clinical practice setting would comprise RA patients in the US. There were an estimated 18 000 current users of tofacitinib in the US (as of September, 2015). To rule out a relative risk of 3 with 80% power for a one-sided test at alpha of 0.05, 21 000 PYs of tofacitinib exposure would be required, achievable with 5250 tofacitinib users, followed up for an average of 4 years, and four times the number of PYs in the comparator population. For such a study to be feasible, several large automated data resources with linkage to the US national death index (eg, Truven, Optum, etc.) would need to be combined. It was deemed that a study designed to rule out a relative risk in the order of 2 would not be feasible with observational data available in the US in the next few years, given estimates of tofacitinib use and the required followup time (54 000 PYs).
| DISCUSSION
As part of the ongoing clinical development of tofacitinib, we identified a signal of pancreatic cancer. The initial preponderance of cases was limited to the psoriasis trial population compared with other indications; however, it should be noted that this finding had no bearing on the decision to discontinue the clinical development program in patients with psoriasis. Among the four cases identified among RA patients, three cases were reported in the Japanese RA postmarketing surveillance study. It is important to recognize that the latter observations are also spontaneous reports from the tofacitinib arm of an observational study.
The body of evidence presented can also be considered using the Bradford Hill framework of causality, which consists of criteria for strength, consistency, specificity, temporality, dose-response, plausibility, coherence, experimental evidence, and analogy. 23 The only causal consideration within the Bradford Hill framework that was clearly met was 'strength of association', demonstrated in elevated incidence rates and SIRs/IRRs. The lack of a signal in other indications in the tofacitinib clinical program (ie, lack of 'consistency') mitigates the strength of association and makes it less likely that the signal is a true positive. Further, in terms of temporality, pancreatic cancer has a long latency period (21 years on average from the initiating event to patient death), 24 rendering induction of pancreatic cancer by tofacitinib implausible, though a role in cancer promotion cannot be excluded.
Review of the 8 confirmed cases revealed established risk factors for pancreatic cancer for the majority of the patients, and for all of the cases from the psoriasis program. Risk factors for pancreatic cancer, such as smoking and diabetes, were prevalent among patients in the psoriasis clinical development program as expected for this patient population. 25 Nonetheless, the observed number of cases was higher than expected even after adjustment for these risk factors. While this imbalance might be accounted for by additional unidentified risk factors, extraordinary conditions would need to be met for this to be the case. For instance, chronic pancreatitis is the strongest risk factor for pancreatic cancer. 11 In order for chronic pancreatitis to explain the magnitude of effect detected, the tofacitinib trial population would need to have a 100-fold greater risk of chronic pancreatitis than the reference population and the relative risk between chronic pancreatitis and pancreatic cancer would need T A B L E 3 Standardized incidence ratio and incidence rate ratio (95% CI) estimates based on pancreatic cancer cases observed in the tofacitinib psoriasis program compared with reference populations Age-gender-, smoking-, and diabetes-adjusted. c 6-month exposure censored. As a sensitivity analysis, SIRs were calculated for only three patients in the psoriasis program based on the feedback from the expert consultants that pancreatic cancer in patients with <6 months of exposure is highly unlikely to be related to tofacitinib. As the reference group is defined based on disease status, as opposed to the start of a particular exposure, and therefore there is no equivalent time frame to remove, the exposure time in the reference groups remained the same. Takes into account variability of external comparator population.
to be in the order of 42, lending credibility to chance or selection bias as alternative explanations.
With regard to selection bias, analogies may be drawn with illnesses such as pancreatitis and recent-onset diabetes, which have been noted to occur in the year or two prior to pancreatic cancer diagnosis. 26 A Swedish study 27 evidence, we believe that tofacitinib exposure is unlikely to be related to the induction or promotion of pancreatic cancer; however, a relationship to promotion cannot be excluded. Pfizer will continue to monitor pancreatic cancer incidence both via routine pharmacovigilance as well as long-term prospective active surveillance efforts. 
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